SecBot SecBot

GSK

GSK plc
NYSE· Pharmaceutical Preparations· Inc. X0· CIK 0001131399 Biotech & Drug Discovery
$50.41 −0.04 (−0.08%)
Nov 16 4:00 PM ET · prev $50.45
Market cap
$102.4B
Large cap
Consensus
Buy
44% Buy or better · 34 analysts
Median target
$58.00
+15% · range $49.00–70.00
1 year
+6.1%
from $47.53 · Nov 17
30 days
+1.9%
from $49.46
52-week range
$46.11–61.18
−18% from high · low Nov 20
Avg volume 20D
3.89M
shares / day
Short interest
16.15M
≈0.8% of shares · +10.8%
Days to cover
3.2
at average volume
New fund stakes
2
Q3 2026 13F · 1 exit
Filing reports
64
analyzed by SecBot
SecBot read BULLISH 34 reports · 90 days
Balance 0 bearish · 10 bullish · 1 mixed · 23 neutral oldest → newest, height = score
Avg score ·High conf. 31/34

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q3 2026: 25 added (2 new), 15 trimmed or exited. Largest new: Aberdeen Group $28.1M, Renaissance Technologies $22.5M.

  • AnalystsBULLISH

    15 of 34 rate it Buy or better. Median target $58.00 (+15%).

  • Short sellersSTEADY

    Short interest +10.8% to 16.15M shares. 3.2 days to cover, ≈0.8% of shares.

  • TrendUPTREND

    2% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 24.

Who's buying

13F· Q3 2026
2
new positions
1
exit
$50.6M
in new stakes
FundMoveSharesValue
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD2,168,669$104.5M
Connor, Clark & Lunn Investment Management Ltd.TRIM2,073,362$99.9M
BANK OF MONTREAL /CAN/TRIM2,023,291$97.5M
JPMORGAN CHASE & COTRIM1,187,161$58.6M
SEI INVESTMENTS COTRIM796,764$38.4M
Aberdeen Group plcNEW583,300$28.1M
RENAISSANCE TECHNOLOGIES LLCNEW466,340$22.5M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ADD422,671$20.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

34 analysts
Buy 44% rate it Buy or better
Strong Buy6Buy9Hold16Sell3Strong Sell0
12-month targets · 9 analysts

Price is inside the target range. Median implies +15%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 29, 2026Jefferies
DOWNGRADE
DOWNGRADEHold

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next QNoneNoneNo data$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
GSK announced that the EMA's CHMP has issued a positive opinion recommending a label update for Bexsero (4CMenB) to…
6-K · Impact 4/10
Nov 12, 2026 SEC
GSK filed a Form 6-K reporting routine share acquisitions by multiple PDMRs (directors and senior executives) under…
6-K · Impact 2/10
Nov 8, 2026 Clinical trial readout
T-90d Trial Readout: FF/UMEC/VI (Phase 3)
Trial: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-ye
Nov 6, 2026 SEC
GSK published provisional dividend dates for 2027, a routine administrative filing with no financial results or…
6-K · Impact 1/10
Oct 20, 2026 Event
HIBSAGO
Original Approval, Type 1 - New Molecular Entity, INJECTION
Sep 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP · ADD
2,168,669 shares ($104.5M)
Sep 30, 2026 Inst.
Connor, Clark & Lunn · TRIM
2,073,362 shares ($99.9M)
Jun 16, 2026 Event
GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC v. Pfizer Inc., Pharmacia & Upjohn Co. LLC, BioNTech SE, BioNTech Manufacturing GmbH, and BioNTech US Inc.; GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC v. Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc.
Court ruling from District Court, D. Delaware. Docket: 1:24-cv-00512

SecBot reports

64 filings · 19 bullish · 2 bearish · 2 mixed · 41 neutral
All GSK filing & press-release reports (64)